NWPF

News Archives

Filtered by: September 2005

Azilect can provide significant additional benefits to levodopa treated Parkinson’s Disease patients

Friday September 30, 2005

New data presented in an oral presentation session, at the 9th congress of the European Federation of Neurological Societies, showed that treatment with Azilect (rasagiline 1 mg) once daily can provide significant additional benefits to levodopa treated patients with moderate to advanced Parkinson’s disease (PD). These benefits were seen regardless of whether patients were receiving additional, optimized treatment with a dopamine agonist.

Read Aricle

Low cholesterol linked to Parkinson’s risk in men

Thursday September 29, 2005

Is it possible to have too low a level of cholesterol? A cholesterol profile that reduces the risk of heart disease may increase the risk for Parkinson’s disease — at least for men — researchers report.

Read Aricle

Ali’s daughter shares book on Parkinson’s Disease

Wednesday September 28, 2005

You only have to say his name and most everyone will know who he is.

Muhammad Ali is legendary in the ring, but the three time world heavyweight champion is a long way from that.

Read Aricle

Ceregene initiates gene therapy trial in Parkinson’s

Wednesday September 28, 2005

The goal of the study is to determine the safety and efficacy of the treatment. Efficacy will be measured by standardized tests for Parkinson’s patients, as well as brain imaging studies.

Read Aricle

Brain inflammation ’initiates’ Parkinson’s

Wednesday September 28, 2005

Researchers in Sydney say they have made a significant discovery about Parkinson’s disease.

The Prince of Wales Medical Research Institute says it has found that the immune system plays a role in the development of the disease by attacking parts of the brain.

Read Aricle

Neurologix announces positive results of gene therapy clinical trial in Parkinson’s disease

Wednesday September 28, 2005

Neurologix’s Phase I trial showed positive interim results in patients with Parkinson’s disease. One year following treatment, patients exhibited a statistically significant improvement in motor function on the side of their body correlating to the treated part of the brain. Further, PET scans at one year revealed that the treated side of the brain exhibited a statistically significant decrease in abnormal metabolism, results considered similar to those achieved with STN Deep Brain Stimulation.

Read Aricle

Parkinson’s drugs may trigger gambling obsession

Tuesday September 20, 2005

Recent reports suggest that pathologic gambling, a severe addiction to gambling, is a rare complication of using anti-Parkinson’s drugs. Now, new research delves deeper into this association and reveals that the gambling may resolve when the drug is stopped and that the drug pramipexole is often implicated.

Read Aricle

Parkinson’s Patient Advocates Call on Amgen to Move Forward with GDNF Clinical Trials

Tuesday September 20, 2005

Sunday’s CBS News program "60 Minutes" profiled several courageous Parkinson’s patients who volunteered for Amgen, Inc.’s clinical trials of glial cell line-derived neurotrophic factor (GDNF), a promising Parkinson’s treatment for which the biotech giant company holds the patent. Today, Tuesday, September 13, 2005, a coalition of grassroots Parkinson’s patients and organizations published an open letter to Amgen President and CEO Kevin Sharer in a full-page ad in the Ventura County Star, where Amgen is headquartered, urging him to restart human trials of the growth factor or license it to a company that will.

Read Aricle

Phase III Date for Rotigotine in Advanced Parkinson’s Disease at EFNS Congress

Tuesday September 20, 2005

MONHEIM, Germany, Sept. 19, 2005 - SCHWARZ PHARMA will release a broad spectrum of clinical and pre-clinical data at the 9th European Federation of Neurological Societies (EFNS) in Athens. Most importantly, the results of a phase III trial conducted in the U.S. with rotigotine transdermal system for the treatment of patients with advanced-stage Parkinson’s disease will be shared for the first time.

Read Aricle

Drug nerve infusion reversed Parkinson’s brain damage

Tuesday September 20, 2005

Neuroscientists at Frenchay hospital in Bristol have reported that the drug GDNF (glial cell line-derived neurotrophic factor) reversed Parkinsons and helped regenerate nerve fibres in a region of the brain called the putamen, which is responsible for the chemical dopamine, crucial for brain cell communication. The findings were reported in Nature Medicine following an autopsy on a Parkinson’s patient’s brain, who had receiving the drug but died of an unrelated heart attack.

Read Aricle
<< Back 1 - 10 of 34 Next >>